Comparison of two methods to obtain a desired first isepamicin peak in intensive care patients

Fundamental and Clinical Pharmacology

Volumn 15, Issue 2, 2001, Pages 151-156

  Fauvelle, Francis ^a   Coulaud, Jean Michel ^a   Lecointre, Karine ^a   Tardy, Dominique ^a   Poussel, Jean François ^a   Trape, Gérard ^b  

^a Centre Hospitalier Intercommunal Le Raincy Montfermeil   (France)

^b Schering Plough   (France)

Author keywords

Bayesian method; Isepamicin; Loading dose; Pharmacokinetics

Indexed keywords

CREATININE; ISEPAMICIN;

ACCURACY; ADULT; AGE; AGED; ARTICLE; ARTIFICIAL VENTILATION; BAYES THEOREM; BLOOD SAMPLING; BODY HEIGHT; BODY WEIGHT; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENDER; HUMAN; INTENSIVE CARE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ADULT; AGED; ANTI-BACTERIAL AGENTS; BAYES THEOREM; CREATININE; FEMALE; GENTAMICINS; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; INTENSIVE CARE UNITS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RESPIRATION, ARTIFICIAL; TREATMENT OUTCOME;

EID: 0035740290     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2001.00020.x     Document Type: Article

References (28)

1. In vivo analysis of structure-activity relationships among four aminoglycosides: Gentamicin, netimicin, 1-NHAPA gentamicin B and amikacin
2. Experimental and clinical studies of Hapa-B
3. Single-dose pharmacokinetics of isepamicin in young and geriatric volunteers
4. The safety and tolerance of three mutidose regimens of isepamicin
5. Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injections
6. Pharmacokinetics of Isepamicin in Childhood
7. Population pharmacokinetic analysis of new aminoglycosides, astromicin and isepamicin, and evaluation of Bayesian prediction method for approximation of individual clearance of drug
8. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections
9. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria
10. Inadequacy of standard aminoglycoside loading dose in acutely ill patients
11. High dose aminoglycoside therapy in surgical intensive care unit patients
12. Aminoglycoside dosing considerations in intensive care unit patients
13. Population pharmacokinetic study of isepamicin with intensive care unit patients
14. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by individualized pharmacokinetic monitoring of patients with pneumonia caused by Gram-negative organisms
15. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: A cost-effectiveness analysis
16. Prediction of creatinine clearance from serum creatinine
17. Biological activity of SCH 21240. The 1-N-S-α-hydroxy-β-aminopropionyl derivative of gentamicin
18. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimum inhibitory concentration
19. The synthesis and biological properties of 1-N-(S-4-amino-2-hydroxybutyryl) -gentamicin B and 1-N-(S-3-amino-2-hydroxypropionyl) -gentamicin
20. Modelling individual pharmacokinetics for computer-aided drug dosage
21. Forecasting individual pharmacokinetics
22. Bayesian individualization of pharmacokinetics: Simple implementation and comparison with non-Bayesian methods
23. Some suggestions for measuring predictive performances
24. Altered aminoglycoside pharmacokinetics in critically ill patients
25. Aminoglycoside volume of distribution and illness severity in critically ill septic patients
26. Changes in gentamicin pharmacokinetic profiles induced by mechanical ventilation
27. Intrapatient variation of aminoglycoside pharmacokinetics in critically ill surgery patients
28. Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease